Literature DB >> 22515275

The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.

Jesse R Schank1, Andrea L Goldstein, Kelly E Rowe, Courtney E King, Julie A Marusich, Jenny L Wiley, F Ivy Carroll, Annika Thorsell, Markus Heilig.   

Abstract

The role of kappa-opioid receptors (KOR) in the regulation of alcohol-related behaviors is not completely understood. For example, alcohol consumption has been reported to increase following treatment with KOR antagonists in rats, but was decreased in mice with genetic deletion of KOR. Recent studies have further suggested that KOR antagonists may selectively decrease alcohol self-administration in rats following a history of dependence. We assessed the effects of the KOR antagonist JDTic on alcohol self-administration, reinstatement of alcohol seeking induced by alcohol-associated cues or stress, and acute alcohol withdrawal-induced anxiety ('hangover anxiety'). JDTic dose-dependently reversed hangover anxiety when given 48 hours prior to testing, a time interval corresponding to the previously demonstrated anxiolytic efficacy of this drug. In contrast, JDTic decreased alcohol self-administration and cue-induced reinstatement of alcohol seeking when administered 2 hours prior to testing, but not at longer pre-treatment times. For comparison, we determined that the prototypical KOR antagonist nor-binaltorphimine can suppress self-administration of alcohol at 2 hours pre-treatment time, mimicking our observations with JDTic. The effects of JDTic were behaviorally specific, as it had no effect on stress-induced reinstatement of alcohol seeking, self-administration of sucrose, or locomotor activity. Further, we demonstrate that at a 2 hours pre-treatment time JDTic antagonized the antinociceptive effects of the KOR agonist U50,488H but had no effect on morphine-induced behaviors. Our results provide additional evidence for the involvement of KOR in regulation of alcohol-related behaviors and provide support for KOR antagonists, including JDTic, to be evaluated as medications for alcoholism. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22515275      PMCID: PMC3334348          DOI: 10.1111/j.1369-1600.2012.00455.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  59 in total

1.  Reduced alcohol consumption in mice lacking preprodynorphin.

Authors:  Yuri A Blednov; Danielle Walker; Marni Martinez; R Adron Harris
Journal:  Alcohol       Date:  2006-10       Impact factor: 2.405

2.  Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats.

Authors:  Andrea Cippitelli; Camilla Karlsson; Janice L Shaw; Annika Thorsell; Donald R Gehlert; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2010-07-14       Impact factor: 4.530

3.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

4.  Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats.

Authors:  S M Hölter; M S Henniger; A W Lipkowski; R Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

5.  Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning.

Authors:  Jay P McLaughlin; Benjamin B Land; Shuang Li; John E Pintar; Charles Chavkin
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

6.  Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms.

Authors:  Xiu Liu; Friedbert Weiss
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats.

Authors:  Roberto Ciccocioppo; Rémi Martin-Fardon; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2002-09       Impact factor: 7.853

8.  Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division.

Authors:  Nathan J Marchant; Valerie S Densmore; Peregrine B Osborne
Journal:  J Comp Neurol       Date:  2007-10-20       Impact factor: 3.215

9.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

10.  D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways.

Authors:  Sheng Chen; Xiaojie Zhang; Dehua Yang; Yunlan Du; Liang Li; Xuping Li; Ming Ming; Weidong Le
Journal:  FEBS Lett       Date:  2008-01-31       Impact factor: 4.124

View more
  47 in total

Review 1.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.

Authors:  Kia J Jackson; Asti Jackson; F Ivy Carroll; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

3.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

Authors:  Pauline W Ondachi; Chad M Kormos; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

Review 4.  Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.

Authors:  Rachel I Anderson; Howard C Becker
Journal:  Alcohol Clin Exp Res       Date:  2017-06-05       Impact factor: 3.455

Review 5.  The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Authors:  Matthew L Banks
Journal:  Handb Exp Pharmacol       Date:  2020

6.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Authors:  Chad M Kormos; Pauline W Ondachi; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

7.  Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.

Authors:  Stephanie L Grella; Douglas Funk; Kathy Coen; Zhaoxia Li; A D Lê
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors.

Authors:  Jessica L Kissler; Sunil Sirohi; Daniel J Reis; Heiko T Jansen; Raymond M Quock; Daniel G Smith; Brendan M Walker
Journal:  Biol Psychiatry       Date:  2013-04-21       Impact factor: 13.382

Review 10.  Dynorphin--still an extraordinarily potent opioid peptide.

Authors:  Charles Chavkin
Journal:  Mol Pharmacol       Date:  2012-11-14       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.